CompletedPhase 4

Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).

Australia1,508 participantsStarted 2005-11

Plain-language summary

This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The treating clinician believes that the patient requires CRRT for acute renal failure.
✓. The clinician is uncertain about the balance of benefits and risks likely to be conferred by treatment with higher intensity or lower intensity CRRT.
✓. The treating clinicians anticipate treating the patient with CRRT for at least 72 hours.
✓. Informed consent has been obtained
✓. The patient fulfils ONE of the following clinical criteria for initiating CRRT:

Exclusion criteria

✕. Patient age is \<18 years.
✕. Death is imminent (\<24 hours).
✕. There is a strong likelihood that the study treatment would not be continued in accordance with the study protocol.
✕. The patient has been treated with CRRT or other dialysis previously during the same hospital admission.
✕. The patient was on maintenance dialysis prior to the current hospitalisation.
✕. The patient's body weight is \<60 kg or \>100kg.
✕. Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.

What they're measuring

Death from all causes at 90 days after randomisation.

Timeframe: Within 90 days after randomisation

Trial details

NCT IDNCT00221013

SponsorThe George Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-10

View on ClinicalTrials.gov More Acute Renal Failure trials